Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
138.00    -3.50 (-2.47%)
Bid:
136.00
Ask:
140.00
Spread: 4.00 (2.941%)
Market Cap: £116.79m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

Presentation at Big Data Belfast

24 Oct 2019 07:00

RNS Number : 9199Q
Diaceutics PLC
24 October 2019
 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Presentation at Big Data Belfast

 

Diaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces that it will attend the Big Data Belfast conference as an invited speaker at the ICC Waterfront in Belfast on 24 October. Big Data Belfast is one of the leading data and technology events on the island of Ireland, driving thought leadership in one of the most exciting and expansive business clusters. This established conference has been running for seven years, featuring global data and analytics experts and best in class data driven organisations.

 

Derek Hosty, Head of Global Data at Diaceutics will deliver a presentation during the Artificial Intelligence and Machine Learning section of the conference entitled 'Using Big Data to make Better Decisions in Healthcare.' The presentation will be available on the Company's website from the end of the day and can be accessed via this link:

https://www.diaceutics.com/using-big-data-to-make-better-decisions-in-healthcare/

 

The Company's proprietary data offering combines diagnostic testing, claims and prescription data providing actionable insights for 115m+ patient records covering 47 deductive pathways in 35 global markets. Diaceutics' presentation will demonstrate how smart application of the Company's data analytics can significantly impact outcomes for patients in need of precision medicine therapies using a case study of metastatic lung cancer.

 

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABUBDGRBDBGCX
Date   Source Headline
1st Jun 20262:00 pmRNSPDMR Shareholding/Share Incentive Plan & TVRs
29th May 20262:00 pmRNSNotice of AGM & Posting of Annual Report
26th May 20267:00 amRNSFinal Results
13th May 20267:00 amRNSNotice of Results
12th May 20262:00 pmRNSHolding(s) in Company
5th May 20267:00 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
16th Apr 20261:11 pmRNSRelated Party Transaction - Lease Extension
7th Apr 20267:00 amRNSBlock Listing Return
1st Apr 202611:59 amRNSPDMR Shareholding/SIP & Total Voting Rights
3rd Mar 202610:56 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
3rd Feb 20268:01 amRNSPDMR Shareholding/Share Incentive Plan & TVR
15th Jan 20267:00 amRNSFull Year 2025 Trading Update
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
28th Nov 202511:53 amRNSPDMR Shareholding/SIP & Total Voting Rights
4th Nov 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
7th Oct 20257:00 amRNSBlock listing Interim Review
1st Oct 202511:40 amRNSPDMR Shareholding/Share Incentive Plan and TVR
23rd Sep 20257:00 amRNSH1 2025 Results
11th Sep 20257:00 amRNSNotice of Results
9th Sep 202510:47 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
11th Aug 202510:58 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDiaceutics at Canaccord Genuity Growth Conference
30th Jul 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Jul 20257:00 amRNS-RDiaceutics Announces Key Leadership Appointment
25th Jul 202512:15 pmRNSHolding(s) in Company
23rd Jul 20257:00 amRNSIssue of Share Options / PDMR Shareholdings
22nd Jul 20257:00 amRNS22% Revenue Growth H125 representing 3-yr CAGR 25%
17th Jul 20257:00 amRNS-RExpansion of PMx Commercialization Partnership
30th Jun 20257:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
18th Jun 202512:00 pmRNSResults of AGM
6th Jun 20259:33 amRNSPDMR Shareholding /Share Incentive Plan and TVR
21st May 20255:00 pmRNSNotice of AGM and Posting of Annual Report
15th May 20257:00 amRNSTransaction by Persons Closely Associated to PDMRs
13th May 20257:00 amRNSFY 2024 Results - Strong Revenue Growth
29th Apr 20254:09 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Apr 20257:00 amRNSNotice of Results
7th Apr 202510:33 amRNSBlock Listing Return
3rd Apr 20251:54 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
26th Mar 20257:00 amRNSPMx Promotional Partner Contract Enhancement
6th Mar 20253:16 pmRNSHolding(s) in Company
3rd Mar 20253:00 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
31st Jan 20259:13 amRNSPurchase of Shares and PDMR Shareholding
30th Jan 202511:27 amRNSPDMR Shareholding/Share Incentive Plan
28th Jan 20257:00 amRNSFY 2024 Trading Update - Strong Revenue Growth
14th Jan 20257:00 amRNSDiaceutics Opens US Headquarters
8th Jan 20257:00 amRNSNew Service Launched & First Contract Signed
3rd Jan 20253:39 pmRNSPDMR Dealings & Total Voting Rights
19th Dec 20248:09 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.